Oral chemotherapeutic agents for colorectal cancer

Oncologist

Volumn 5, Issue 2, 2000, Pages 99-107

  Sharma, Sunil ^a   Saltz, Leonard B ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Colon cancer; Economic analysis; Oral chemotherapy; Patient compliance; Rectal cancer

Indexed keywords

5 ETHYNYLURACIL; 9 AMINOCAMPTOTHECIN; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FOLINATE CALCIUM; IRINOTECAN; LONAFARNIB; ORZEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RUBITECAN; TIPIFARNIB; UFT;

ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; FATIGUE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; VOMITING;

EID: 0034049660     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-99     Document Type: Article

References (69)

1. Landis SH, Murray T, Bolden S et al. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
2. Cohen A, Minsky B, Schilsky P. Colorectal cancer. In: De Vita V, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1993:929-977.
3. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557-2567.
4. Lee CR, Nicholson PW, Souhami RL et al. Patient compliance with oral chemotherapy as assessed by a novel oral technique. J Clin Oncol 1992;10:1007-1013.
5. Ishitsuka H, Miwa M, Ishikawa T et al. Capecitabine: an orally available fluoropyrimidine with tumor selectivity. Proc Am Assoc Cancer Res 1995;36:2426a.
6. Ishikawa T, Sawada N, Sekiguchi F et al. Xeloda (capecitabine) a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Proc Am Soc Clin Oncol 1997:16:796a.
7. Cao S, Lu K, Ishitsuka H et al. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors. Proc Am Soc Clin Oncol 1997:16:795a.
8. Schuller J, Reigner BG, Durston S et al. Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 1997;16:797a.
9. Takebayashi, Y, Yamada K, Maruyama I et al. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. Cancer Lett 1995;25:1-7
10. Meropol N, Budman D, Creaven P et al. A phase I study of continuous twice daily treatment with capecitabine in patients with advanced and/or metastatic tumors. Ann Oncol 1996;7(suppl 1):298a.
11. Hughes M, Planting A, Twelves C et al. A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer. Ann Oncol 1996;7(suppl 1):297a.
12. Osterwalder B, Reigner B. Pharmacokinetics (PK) and pharmacodynamics (PD) of capecitabine in two phase I studies. Proc Am Soc Clin Oncol 1996;15:727a.
13. Findlay M, Van Custem E, Kocha W et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:798a.
14. Twelves C, Harper P, Van Custem E et al. A phase III trial (S014796) of Xeloda in previously untreated advanced/ metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:1010a.
15. Cox JV, Pazdur R, Thibault A et al. A phase III trial of Xeloda in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:1016a.
16. El Sayed YM, Sadee W. Metabolic activation of ftorafur [R,S-1(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Biochem Pharmacol 1982;31:3006-3008.
17. Ohyama K, Koike D, Odake Y et al. Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region. Jpn J Cancer Chemother 1982;9:2168-2174.
18. Fukui T, Imbayashi N, Nishi M et al. Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Jpn J Cancer Chemother 1980;7:2124-2129.
19. Futatsuki K, Komita T, Kamano T. Clinical results of treatment with the UFT fine granule preparation under cooperative study. Tokyo Cancer Chemotherapy Cooperative Study Group. Jpn J Cancer Chemother 1987;14:1274-1280.
20. Muggia F, Wu X, Spicer D et al. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. Clin Cancer Res 1996;2:1461-1467.
21. Pazdur R, Covington WP, Brown NS et al. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU). Proc Am Soc Clin Oncol 1996;474:1948a.
22. Pazdur R, Lassere Y, Diaz-Canton E et al. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule dependent toxicities. Anticancer Res 1996;7:728-733.
23. Okabe H, Toko T, Saito H et al. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral 1-leucovorin. Anticancer Res 1997;17:157-164.
24. Pazdur R, Lassere Y, Rhodes V et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296-2300.
25. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:1009a.
26. Mok TSK, Leung TWT, Chan ATC et al. A phase III randomized study of oral UFT (tegafur + uracil) as maintenance therapy in adjuvant treatment of surgically resected colorectal cancer patients. Proc Am Soc Clin Oncol 1998;17:1042a.
27. Hoff PM, Brito R, Slaughter M et al. Preoperative UFT, oral leucovorin (LV) and radiotherapy (RT) for patients with resectable rectal carcinoma: an oral regimen with complete pathologic responses. Proc Am Soc Clin Oncol 1998;17:860a.
28. Espinosa E, Gonzalez-Baron M, Feliu J et al. UFT-leucovorin as adjuvant treatment for Duke's B2-C colon cancer. Proc Am Soc Clin Oncol 1998;17:1059a.
29. Sadahiro S, Ohki S, Takahashi T et al. Pilot study on the new dose intensive oral UFT schedule as adjuvant chemotherapy for colorectal cancer. Proc Am Soc Clin Oncol 1998;17:1054a.
30. Schoffski P, Vermoken J, Schellens J et al. Safety, toxicity and antitumor efficacy of the modulated oral fluoropyrimidine derivative S-1 in patients with metastatic colorectal cancer: preliminary results of an early phase II study. Clin Cancer Res 1999;5(suppl):S3772.
31. Cao S, Rustum YM, Spector T. 5-Ethinyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994;54:1507-1510.
32. Ahmed FY, Johnston SJ, Cassidy J et al. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal cancers. J Clin Oncol 1999;17:2439-2445.
33. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993;46:2243-2248.
34. Schilsky RL, Hohneker J, Ratain MJ et al. Phase I and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 1998;16:1450-1457.
35. Baker SD, Khor SP, Adjei AA. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 1996;14:3085-3096.
36. Mani S, Beck T, Chevlen E et al. A phase II open label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998;18:1083a.
37. Schilsky R, Bukowski R, Burris H et al. A phase II study of 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:271a.
38. Matei S, Hoff PM, Brito R et al. Phase I trial of oral BOF-A2 plus leucovorin (LV) in advanced colorectal cancer: anti-tumor activity in fluorouracil-resistant patients. Proc Am Soc Clin Oncol 1998;18:882a
39. D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990;50:6919-6924.
40. Houghton PJ, Clinton FS, Zamboni WC et al. Schedule dependent efficacy of camptothecins in models of human cancer. Ann N Y Acad Sci 1996;803:188-201.
41. Drengler RA, Kuhn JG, Schaaf LJ et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999;17:685-696.
42. Mani S, Iyer L, Janisch L et al. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 1998;42:84-87.
43. Sparreboom A, Stoter G, Loos WJ et al. Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors. Proc Am Assoc Cancer Res 1997;38:504a.
44. Pazdur R, Medgysey DC, Winn RJ et al. Phase II trial of 9-aminocamptothecin administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal cancer. Invest New Drugs 1998;16:341-346.
45. Pazdur R, Diaz-Canton E, Ballard WP et al. Phase II trial of 9-Aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997;15:2905-2909.
46. Saltz LB, Kemeny NE, Tong W et al. 9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal cancer. Cancer 1997;80:1727-1732.
47. Verschraegen CF, Natelson EA, Giovanella BC et al. A phase I clinical and pharmacological study of oral 9-nitrocamtothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998;9:36-44.
48. Bollag G, McCormick F. Regulators and effectors of ras proteins. Annu Rev Cell Dev Biol 1991;7:601-632.
49. Liu M, Bryant MS, Chen J et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-4956.
50. Hurwitz HI, Colvin OM, Petros WP et al. Phase I and pharmacokinetic study of SCH 66336, a novel FPTI, using a 2-week on, 2-week off schedule. Proc Am Soc Clin Oncol 1999;18:599a.
51. Eskens E, Awada A, Verweij J et al. Phase I and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 1999;18:600a.
52. Awada A, Eskens F, Piccart MJ et al. A clinical and pharmacokinetic study of SCH 66336(SCH) an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors. Clin Cancer Res 1999;5(suppl):S3733.
53. Skrzat S, Angibaud P, Venet M et al. R115777, a novel imidazole farnesyl transferase inhibitor (FTI) with potent oral antitumor activity. Proc Am Assoc Cancer Res 1998;39:2170a.
54. Hudes GR, Schol J, Baab J et al. Phase I clinical and pharmacologic trial of the farnesylation inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 1999;18:601a.
55. Zujewski J, Horak ID, Bol CJ et al. A phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777, in advanced cancer. J Clin Oncol 2000;18:927.
56. Peeters M, Van Cutsem E, Marse H et al. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal (CRC) or pancreatic cancer (PC). Proc Am Soc Clin Oncol 1999;18:858a.
57. Okuda H, Ogura K, Kato A et al. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287:791-799.
58. Wakisaka S, Shimauchi M, Kaji Y et al. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi 1990;81:192-196.
59. Douillard JY, Cunningham D, Roth AD et al. A randomized phase III trial comparing irinotecan+5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients with metastatic colorectal cancer (MCRC) as front-line chemotherapy. Proc Am Soc Clin Oncol 1999;18:899a.
60. Saltz LB, Locker PK, Elfring GL et al. Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily X 5 LV/FU in patients with previously untreated colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999;18:898a.
61. Van Cutsem E, Szanto J, Roth A et al. Evaluation of the addition of oxaliplatin to the same mayo or german 5-FU regimen in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 1999;18:900a.
62. Feliu J, Calvillo J, Escribano A et al. Neoadjuvant therapy of rectal carcinoma with UFT-folinic acid (LV) plus radiotherapy. Proc Am Soc Clin Oncol 1999;18:917a.
63. Lokich JJ, Moore CL, Anderson NR. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors - Part one. Cancer 1996;78:294-299.
64. Lokich JJ, Moore CL, Anderson NR. Comparisons of costs of infusion versus bolus chemotherapy administration - Part two. Cancer 1996;78:300-303.
65. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
66. Saltz LB, Leichman CG, Young CW et al. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782-785.
67. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 1994;24:322-326.
68. Gonzalez-Baron M, Feliu J, Garcia Giron C et al. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience. Oncology 1997;54(suppl 1):24-29.
69. 1999 Drug Topics - Red Book. Montvale, NJ: Medical Economics Company, 1999.